2025 Q2 -tulosraportti
198 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 800 | - | - | ||
| 18 867 | - | - | ||
| 3 000 | - | - | ||
| 5 963 | - | - | ||
| 1 021 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenI want to bring some clarity to this feasibility study, which is one of the reasons the stock has gone up a lot lately, and has the potential to go up more. It is therefore one of the largest Big Pharma companies in the world that is paying Circio to replicate its results either in its own laboratory or possibly under their supervision, with their tests and systems. So why are they doing this? The purpose is to build trust and ensure that the studies are correct before a license or co-development agreement. In other words, such an agreement is veeeery likely. Such an agreement usually entails an upfront payment and then Milestone payments as development progresses or products are rolled out, before eventual royalties or acquisition. The upfront payment depends on whether it is a platform that can be used for multiple therapies/diseases (like Circvec) and whether the agreement is exclusive. The upfront payment could be 10-20 mill USD. With expected Milestone payments, it could easily justify a value of 1.5 billion USD for the Circvec platform in the preclinical phase, i.e., when the agreement is signed. This is according to chatgpt with other comparable companies. But if they succeed in clinical trials, the value shoots up many billions. And if they bring finished products to market, we're talking many, many billions. But this is possibly a bit further down the road. Then there are pitfalls. Perhaps they won't get the same results in the feasibility study. Perhaps Circvec doesn't work the same way in humans as in mice. One doesn't know yet. But it is an incredibly exciting stock with great potential to do 10x within a couple of years.
·37 min sittenThanks for the nice post. Do you have a link to that about the big Big Pharma company, and that they pay to reproduce the results in their lab?
·1 t sittenI'm surprised by how many new investors have the patience of a 7-year-old. No offense intended, but for the unseasoned investor (regardless of stock choice), day-trading is often synonymous with loss of money. Absolutely, you can get lucky, but more often than not, you won't. I've been there myself many years ago, among other things, playing with oil certificates and making quick money. Which in the end only led to overconfidence, ill-considered purchases, gambling, and further losses. I'm not writing this to interfere with what you do with your money, but it's almost easy to make money in the long term. So why short term? I find it sad that the forum here, which could have been of great help to many who want to learn about companies, economics, or discuss things other than rockets, is largely bombarded with questions regarding probability and d2d-stock prices. Even Flashback manages to stay more relevant than this. With that said, those of you who actually contribute to a fruitful discourse deserve credit!
·2 t sittenWhat do you think this will be at by the end of next week?
·2 t sittenSitting on the top 100 list for the last three days. Friday is probably not booked and therefore not updated. No major changes at the top, which is very strong. In addition to a couple of banks from the continent that have increased. Including UBS Switzerland. Roche is probably Swiss, or maybe a tax evader, hehe🥸 Attaching this from tekinvestor. Credit, Krohn, assume he reads here too. « Number of Nordnet owners is increasing sharply, now to just over 6k Imagine if it goes up to 10k, then 4000 new owners will come in, I don't know what the average number might be, but take for example 5000 shares then, that gives 4k*5k=20 000 000, i.e. 10 percent of the number of shares in the company ( so it could be that the average is much higher, or lower ) In comparison, Thor medical today has 10400 owners, ( without comparing companies), Nel has over 19k owners in Nordnet.»·47 min sittenHe who seeks, finds. Top 100 is between 12.000.000 - 350.000 units approx.- ·2 t sittenHow is the distribution between shares and warrants for those of you who have both? And what do you expect from your warrants' price?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
198 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenI want to bring some clarity to this feasibility study, which is one of the reasons the stock has gone up a lot lately, and has the potential to go up more. It is therefore one of the largest Big Pharma companies in the world that is paying Circio to replicate its results either in its own laboratory or possibly under their supervision, with their tests and systems. So why are they doing this? The purpose is to build trust and ensure that the studies are correct before a license or co-development agreement. In other words, such an agreement is veeeery likely. Such an agreement usually entails an upfront payment and then Milestone payments as development progresses or products are rolled out, before eventual royalties or acquisition. The upfront payment depends on whether it is a platform that can be used for multiple therapies/diseases (like Circvec) and whether the agreement is exclusive. The upfront payment could be 10-20 mill USD. With expected Milestone payments, it could easily justify a value of 1.5 billion USD for the Circvec platform in the preclinical phase, i.e., when the agreement is signed. This is according to chatgpt with other comparable companies. But if they succeed in clinical trials, the value shoots up many billions. And if they bring finished products to market, we're talking many, many billions. But this is possibly a bit further down the road. Then there are pitfalls. Perhaps they won't get the same results in the feasibility study. Perhaps Circvec doesn't work the same way in humans as in mice. One doesn't know yet. But it is an incredibly exciting stock with great potential to do 10x within a couple of years.·37 min sittenThanks for the nice post. Do you have a link to that about the big Big Pharma company, and that they pay to reproduce the results in their lab?
- ·1 t sittenI'm surprised by how many new investors have the patience of a 7-year-old. No offense intended, but for the unseasoned investor (regardless of stock choice), day-trading is often synonymous with loss of money. Absolutely, you can get lucky, but more often than not, you won't. I've been there myself many years ago, among other things, playing with oil certificates and making quick money. Which in the end only led to overconfidence, ill-considered purchases, gambling, and further losses. I'm not writing this to interfere with what you do with your money, but it's almost easy to make money in the long term. So why short term? I find it sad that the forum here, which could have been of great help to many who want to learn about companies, economics, or discuss things other than rockets, is largely bombarded with questions regarding probability and d2d-stock prices. Even Flashback manages to stay more relevant than this. With that said, those of you who actually contribute to a fruitful discourse deserve credit!
- ·2 t sittenWhat do you think this will be at by the end of next week?
- ·2 t sittenSitting on the top 100 list for the last three days. Friday is probably not booked and therefore not updated. No major changes at the top, which is very strong. In addition to a couple of banks from the continent that have increased. Including UBS Switzerland. Roche is probably Swiss, or maybe a tax evader, hehe🥸 Attaching this from tekinvestor. Credit, Krohn, assume he reads here too. « Number of Nordnet owners is increasing sharply, now to just over 6k Imagine if it goes up to 10k, then 4000 new owners will come in, I don't know what the average number might be, but take for example 5000 shares then, that gives 4k*5k=20 000 000, i.e. 10 percent of the number of shares in the company ( so it could be that the average is much higher, or lower ) In comparison, Thor medical today has 10400 owners, ( without comparing companies), Nel has over 19k owners in Nordnet.»·47 min sittenHe who seeks, finds. Top 100 is between 12.000.000 - 350.000 units approx.
- ·2 t sittenHow is the distribution between shares and warrants for those of you who have both? And what do you expect from your warrants' price?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 800 | - | - | ||
| 18 867 | - | - | ||
| 3 000 | - | - | ||
| 5 963 | - | - | ||
| 1 021 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
198 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenI want to bring some clarity to this feasibility study, which is one of the reasons the stock has gone up a lot lately, and has the potential to go up more. It is therefore one of the largest Big Pharma companies in the world that is paying Circio to replicate its results either in its own laboratory or possibly under their supervision, with their tests and systems. So why are they doing this? The purpose is to build trust and ensure that the studies are correct before a license or co-development agreement. In other words, such an agreement is veeeery likely. Such an agreement usually entails an upfront payment and then Milestone payments as development progresses or products are rolled out, before eventual royalties or acquisition. The upfront payment depends on whether it is a platform that can be used for multiple therapies/diseases (like Circvec) and whether the agreement is exclusive. The upfront payment could be 10-20 mill USD. With expected Milestone payments, it could easily justify a value of 1.5 billion USD for the Circvec platform in the preclinical phase, i.e., when the agreement is signed. This is according to chatgpt with other comparable companies. But if they succeed in clinical trials, the value shoots up many billions. And if they bring finished products to market, we're talking many, many billions. But this is possibly a bit further down the road. Then there are pitfalls. Perhaps they won't get the same results in the feasibility study. Perhaps Circvec doesn't work the same way in humans as in mice. One doesn't know yet. But it is an incredibly exciting stock with great potential to do 10x within a couple of years.·37 min sittenThanks for the nice post. Do you have a link to that about the big Big Pharma company, and that they pay to reproduce the results in their lab?
- ·1 t sittenI'm surprised by how many new investors have the patience of a 7-year-old. No offense intended, but for the unseasoned investor (regardless of stock choice), day-trading is often synonymous with loss of money. Absolutely, you can get lucky, but more often than not, you won't. I've been there myself many years ago, among other things, playing with oil certificates and making quick money. Which in the end only led to overconfidence, ill-considered purchases, gambling, and further losses. I'm not writing this to interfere with what you do with your money, but it's almost easy to make money in the long term. So why short term? I find it sad that the forum here, which could have been of great help to many who want to learn about companies, economics, or discuss things other than rockets, is largely bombarded with questions regarding probability and d2d-stock prices. Even Flashback manages to stay more relevant than this. With that said, those of you who actually contribute to a fruitful discourse deserve credit!
- ·2 t sittenWhat do you think this will be at by the end of next week?
- ·2 t sittenSitting on the top 100 list for the last three days. Friday is probably not booked and therefore not updated. No major changes at the top, which is very strong. In addition to a couple of banks from the continent that have increased. Including UBS Switzerland. Roche is probably Swiss, or maybe a tax evader, hehe🥸 Attaching this from tekinvestor. Credit, Krohn, assume he reads here too. « Number of Nordnet owners is increasing sharply, now to just over 6k Imagine if it goes up to 10k, then 4000 new owners will come in, I don't know what the average number might be, but take for example 5000 shares then, that gives 4k*5k=20 000 000, i.e. 10 percent of the number of shares in the company ( so it could be that the average is much higher, or lower ) In comparison, Thor medical today has 10400 owners, ( without comparing companies), Nel has over 19k owners in Nordnet.»·47 min sittenHe who seeks, finds. Top 100 is between 12.000.000 - 350.000 units approx.
- ·2 t sittenHow is the distribution between shares and warrants for those of you who have both? And what do you expect from your warrants' price?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 800 | - | - | ||
| 18 867 | - | - | ||
| 3 000 | - | - | ||
| 5 963 | - | - | ||
| 1 021 | - | - |
Välittäjätilasto
Dataa ei löytynyt